Patel Mona Chetan 4

4 · Envoy Medical, Inc. · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 17, 2026

Envoy Medical (COCH) Director Mona C. Patel Buys 312,500 Shares

What Happened

Mona Chetan Patel, a director of Envoy Medical, reported acquiring a total of 812,500 shares on 2026-02-12. The reported activity includes a cash purchase of 312,500 shares at $0.40 each (total $125,000) plus two derivative-based acquisitions of 187,500 and 312,500 shares at $0.00 (total 500,000 derivative shares).
The cash purchase is a straightforward open-market/private purchase (transaction code P) and is a buy signal. The $0.00 entries are derivative transactions (warrants/options or similar instruments) — these did not require cash payment at the time of reporting but are subject to the terms described in the footnotes.

Key Details

Transaction date: February 12, 2026.
Prices and totals: 312,500 shares @ $0.40 = $125,000 (cash purchase); 187,500 and 312,500 shares @ $0.00 = $0 (derivative acquisitions). Total shares acquired: 812,500.
Shares owned after the transaction: not provided in the material you supplied.
Footnotes of note:
- F1: Some options vest over time (initial tranche and monthly pro rata vesting).
- F2: Certain instruments are exercisable only upon shareholder approval to issue Class A shares.
- F3/F4: Series A-1 and A-2 warrants include expiration conditions tied to FDA filing/approval milestones for the Acclaim CI Device.
Filing timeliness: Report filed 2026-02-17 for transactions dated 2026-02-12. This filing appears to be within the SEC’s business-day window (no late filing flag indicated).

Context

The derivative entries reflect acquisition via warrants/options or similar instruments rather than additional cash purchases. Such derivative shares may be subject to vesting, shareholder approval, or exercise/expiration conditions (see footnotes).
Purchases by company insiders can be informative to investors because they increase the insider’s ownership; derivative acquisitions can be more complex and depend on future approvals or vesting schedules. This summary is factual and does not speculate on the insider’s motivation.

Form 4

Period: 2026-02-12

Director

Transactions

Purchase
Class A Common Stock
2026-02-12$0.40/sh+312,500$125,000→ 332,500 total
Purchase
Warrant (right to buy)
[F2][F3]
2026-02-12+187,500→ 187,500 total
Exercise: $0.40→ Class A Common Stock (187,500 underlying)
Purchase
Warrant (right to buy)
[F2][F4]
2026-02-12+312,500→ 312,500 total
Exercise: $0.40→ Class A Common Stock (312,500 underlying)

Holdings

Stock Option (right to buy)
[F1]
Exercise: $2.40Exp: 2033-10-15→ Class A Common Stock (25,000 underlying)
25,000
Stock Option (right to buy)
Exercise: $0.81From: 2026-05-01Exp: 2035-12-03→ Class A Common Stock (25,000 underlying)
25,000

Footnotes (4)

[F1]Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
[F2]Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
[F3]The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
[F4]The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

Signature

/s/ Andrew Nick as Attorney-in-Fact for Mona Chetan Patel pursuant to Power of Attorney previously filed.|2026-02-16

1 file